Biohaven(BHVN)
NEW HAVEN, CTBiotechnology
Focus: Biohaven is a publicly-traded biotech focused on small-molecule therapeutics for neurology, psychiatry, and rare neurological diseases. The company maintains a diverse pipeline across multiple therapeutic areas with a market presence via NASDAQ ticker BHVN.
Profile data last refreshed 19h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Biohaven
AI assessmentNot HiringNo open roles listed right now. Follow Biohaven to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Biohaven's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Riluzole
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT03537807Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
N/AHelp build intelligence for Biohaven
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.